Omeros Corporation

NasdaqGM:OMER Stock Report

Market Cap: US$349.4m

Omeros Management

Management criteria checks 2/4

Omeros' CEO is Greg Demopulos, appointed in Jun 1994, has a tenure of 30.42 years. total yearly compensation is $7.69M, comprised of 11.9% salary and 88.1% bonuses, including company stock and options. directly owns 3.5% of the company’s shares, worth $12.22M. The average tenure of the management team and the board of directors is 4.9 years and 17.9 years respectively.

Key information

Greg Demopulos

Chief executive officer

US$7.7m

Total compensation

CEO salary percentage11.9%
CEO tenure30.4yrs
CEO ownership3.5%
Management average tenure4.9yrs
Board average tenure17.9yrs

Recent management updates

Recent updates

Omeros Q3 2024 - Updates On OMIDRIA And Narsoplimab Lead To Liquidity Concerns

Nov 17

Omeros: Troubled Company Working Its Way Out Of The Morass

Jul 19

Omeros: Still Worth A Look Despite Narsoplimab Woes

Feb 14

Is Omeros (NASDAQ:OMER) A Risky Investment?

Jul 26
Is Omeros (NASDAQ:OMER) A Risky Investment?

Omeros (NASDAQ:OMER) Is Making Moderate Use Of Debt

Mar 17
Omeros (NASDAQ:OMER) Is Making Moderate Use Of Debt

Omeros: Taking It To The Max

Oct 05

Omeros falls 11% after reporting clinical data for COVID-19 therapy

Sep 15

Omeros: Managing An Investment After A Winning Trade

Aug 16

Omeros granted FDA’s Orphan Drug designation for PNH candidate

Jul 28

Omeros: Follow The Bouncing Ball

Jul 04

Omeros: On Death's Door

Jun 02

Omeros: The Weight Of The Wait, A Conundrum

May 03

Omeros: Despite Its Promise, The CRL Is A Huge Obstacle

Feb 21

Omeros: A New Year Beckons

Dec 06

Some Analysts Just Cut Their Omeros Corporation (NASDAQ:OMER) Estimates

Dec 04
Some Analysts Just Cut Their Omeros Corporation (NASDAQ:OMER) Estimates

Omeros: What's Left

Oct 15

Omeros: The Prize Is Nigh (Again)

Sep 14

Omeros: PDUFA Delay Presents An Opportunity

Jul 03

Omeros posts preliminary results from early-stage OMS906 trial

Jun 09

Should Shareholders Reconsider Omeros Corporation's (NASDAQ:OMER) CEO Compensation Package?

Jun 05
Should Shareholders Reconsider Omeros Corporation's (NASDAQ:OMER) CEO Compensation Package?

Omeros posts preliminary results from COVID-19 patients treated with narsoplimab

May 28

CDC and CMS OKs Omeros' ICD-10 codes for HSCT-TMA diagnosis and narsoplimab

May 04

CEO Compensation Analysis

How has Greg Demopulos's remuneration changed compared to Omeros's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$185m

Jun 30 2024n/an/a

-US$200m

Mar 31 2024n/an/a

-US$179m

Dec 31 2023US$8mUS$917k

-US$175m

Sep 30 2023n/an/a

-US$182m

Jun 30 2023n/an/a

-US$185m

Mar 31 2023n/an/a

-US$182m

Dec 31 2022US$4mUS$882k

-US$182m

Sep 30 2022n/an/a

-US$183m

Jun 30 2022n/an/a

-US$173m

Mar 31 2022n/an/a

-US$181m

Dec 31 2021US$7mUS$848k

-US$192m

Sep 30 2021n/an/a

-US$217m

Jun 30 2021n/an/a

-US$211m

Mar 31 2021n/an/a

-US$194m

Dec 31 2020US$6mUS$817k

-US$173m

Sep 30 2020n/an/a

-US$130m

Jun 30 2020n/an/a

-US$108m

Mar 31 2020n/an/a

-US$89m

Dec 31 2019US$5mUS$794k

-US$147m

Sep 30 2019n/an/a

-US$79m

Jun 30 2019n/an/a

-US$102m

Mar 31 2019n/an/a

-US$121m

Dec 31 2018US$5mUS$770k

-US$127m

Sep 30 2018n/an/a

-US$120m

Jun 30 2018n/an/a

-US$88m

Mar 31 2018n/an/a

-US$68m

Dec 31 2017US$5mUS$748k

-US$53m

Compensation vs Market: Greg's total compensation ($USD7.69M) is above average for companies of similar size in the US market ($USD2.18M).

Compensation vs Earnings: Greg's compensation has increased whilst the company is unprofitable.

CEO

Greg Demopulos (65 yo)

30.4yrs

Tenure

US$7,689,843

Compensation

Dr. Gregory A. Demopulos, M.D., also known as Greg, founded Omeros Corporation in June 1994 and has been its Chairman of the Board, Chief Executive Officer and President since June 1994. Dr. Demopulos serv...

Leadership Team

NamePositionTenureCompensationOwnership
Gregory Demopulos
Co-Founder30.4yrsUS$7.69m3.5%
$ 12.2m
Peter Cancelmo
VP, General Counsel & Corporate Secretary5.4yrsUS$852.63k0.00035%
$ 1.2k
Pamela Palmer
Co-Founderno datano datano data
David Borges
VP of Financeless than a yearno data0.052%
$ 180.9k
George Gaitanaris
Chief Scientific Officer & VP of Science12.8yrsno datano data
Peter Williams
Vice President of Human Resources4.4yrsno datano data
Catherine Melfi
Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems12.1yrsno datano data
Nadia Dac
VP & Chief Commercial Officer3.8yrsno datano data
Andreas Grauer
VP & Chief Medical Officer1.1yrsno datano data

4.9yrs

Average Tenure

61yo

Average Age

Experienced Management: OMER's management team is considered experienced (4.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Gregory Demopulos
Co-Founder30.4yrsUS$7.69m3.5%
$ 12.2m
Thomas Cable
Lead Independent Director29.8yrsUS$177.60k0.061%
$ 211.4k
Leroy Hood
Independent Director23.7yrsUS$135.10k0.13%
$ 448.6k
Arnold Hanish
Independent Director12.2yrsUS$137.60k0.021%
$ 74.8k
Peter Demopulos
Director29.8yrsUS$122.60k0.64%
$ 2.2m
Thomas Bumol
Independent Director5.8yrsUS$127.60k0.017%
$ 60.3k
Rajiv Shah
Independent Director9.4yrsUS$140.10k0%
$ 0
Diana Perkinson
Independent Director1.5yrsUS$174.66k0%
$ 0

17.9yrs

Average Tenure

70yo

Average Age

Experienced Board: OMER's board of directors are seasoned and experienced ( 17.9 years average tenure).